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98S Abstracts May Supplement 2013amputation. The impact of social context is tested by
including patients from the US and Tanzania (TNZ).
Methods: MLE amputees were recruited from US and
TNZ sites in a prospective study. Data collected included
demographic, social integration (CHART), walking func-
tion (Six Minute Walk Test) and QoL (EQ5D). c2 and
ANOVA tests were used to assess association between social
integration and outcomes. Multivariable logistic regression
analysis, was performed to assess the role of social context.
Results: Of the 90 enrolled patients, 50 (56%) were
from the US, 58 (64%) were male, with a mean age of
64.4 years. Patients with high social integration had a trend
toward improved function deﬁned by a score of 171 meters
or better (36% v 66% v 74%; P ¼ .055) and signiﬁcantly
higher mean EQ5D scores (0.65 v 0.70 v 0.79; P ¼
.021). Findings were more dramatic in the US sub-group
for both function (17% v 38% v 74%; P ¼ .008) and
QoL (0.52 v 0.58 v 0.79; P ¼ .001). In a multivariate anal-
ysis, the TNZ site was not associated with less favorable
function (P ¼ .783) or QoL (P ¼ .364).
Conclusions: In the US population, increased social
integration is associated with both improved function and
quality of life outcomes among amputees. This effect is
attenuated in TNZ, likely due to differences in social
context. Steps should be taken to identify and aid amputees
with poor social integration in the US and factors associ-
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Objectives: While many vascular surgeons follow the
algorithm of postoperative bypass vascular evaluation
including non-invasive ﬂow studies (NIFS) and bypass graft
duplex (BGD) at 1, 3, 6 months and annually thereafter,
the data surrounding this recommendation is low. It has
been shown that routine BGD scanning following autoge-
nous lower extremity bypass has not proven to be cost-
effective. The TASC II document recommends a biannual
assessment of exercise NIFS for 2 years postoperatively as
level C evidence. Superﬁcial Femoral Artery (SFA) Percuta-
neous Transluminal Angioplasty/Stent (PTA/S) trials have
required similar schedules of postprocedure evaluation. We
chose to evaluate the beneﬁt of postprocedure imaging.
Methods: We undertook a retrospective review of
a prospective database looking at SFA intervention. The
number of follow up visits, frequency of changes in exam,
changes in postprocedure NIFS and BGD were analyzed.
Results: 104 patients had SFA interventions (46 PTA,
46 PTA/stent, 8 atherectomy, 4 PTA/lysis). Initial studies
(NIFS and/or BGD) within 1-7 weeks showed a change
(ABI < .7 and/or 4:1 peak systolic velocity ratio) in
3.1% of cases, at 3 months an additional 41% showed
change (RR > 1.0; P < .05); at 6 months only an addi-
tional 8% showed change (RR < 1.0; P > 0.05). Kaplan
Meier analysis revealed a lack of signiﬁcance at the 1 year
mark and beyond due decreased follow up.
Conclusions: Of the 547 postprocedure perfusion
assays performed in these 104 patients the statistically
signiﬁcant interval appears to be at the 3 month post-
procedure visit. While the initial study acts as a baseline
the utility of further testing does not appear to add signif-
icant additional information on a cohort basis. Like algo-
rithms for distal bypass there did appear to be better
correlation when coupled with return of symptoms and
or change in physical exam.
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Objectives: Despite patent bypass grafts, some
patients receive major amputations (MA). We analyzed
the frequency and predictive factors leading to MA in the
presence of patent lower extremity bypass grafts (LEB).
Methods: Data from PREVENT III, a large prospec-
tive randomized trial of 1404 patients who underwent LEB
for critical limb ischemia (CLI) was queried for outcomes.
The primary endpoint was MA with patent (PMA) or
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Volume 57, Number 5S Abstracts 99Soccluded (OMA) LEB. Variables identiﬁed on univariate
analysis (inclusion threshold P < .08) were included in
a multivariable logistic regression model to identify inde-
pendent predictors.
Results: Of 1404 LEB patients, 162 (11.5%) had MA,
89 (6.3%) with patent and 73 (5.2%) with occluded LEB.
For PMA, 21 (23.6%) had critical graft stenosis, of which
17 (81.0%) underwent revision, with mean time to revision
of 50.76 days (SD 6 55.49). Minority race (OR, 2.69;
CI, 1.28-5.66; P ¼ .0092), diabetes (OR, 4.14; CI,
1.20-14.24; P ¼ .025), lower baseline activity score (OR,
1.92; CI, 1.24-2.98; P ¼ .0036), and negative change in
3-month activity (OR, 1.61; CI, 1.22-2.13; P ¼ .0007)
were predictors for PMA, while tissue loss was not predic-
tive (OR, 2.32; CI, 0.66-8.08; P ¼ .19).
For OMA, 64 (87.7%) had critical graft stenosis but
only 35 (54.7%) underwent revision, with mean time to
revision of 76.11 days (SD 6 80.14) and mean time to
MA of 107.37 days (SD 6 103.39).
Conclusions: PMA patients had lower rates of graft
stenosis, but were revised earlier than their OMA counter-
parts. Non-graft-related factors (demographic and func-
tional activity) also inﬂuenced PMA. Further investigation
into PMA may optimize treatment decisions.
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Objectives: To evaluate long term outcomes and sac
volume (SV) shrinkage after endovascular popliteal artery
aneurysm repair (EVPAR).
Methods: A retrospective review of EVPAR cases per-
formed between January 1999 and December 2012. SV
shrinkage, long term patency, limb salvage (LS), and
survival (S) were evaluated with K-M estimates. Anatomical
characteristics and clinical presentation were evaluated for
their association with patency using multiple logistic
regression.
Results: 46 EVPAR procedures in 42 patients. Mean
age was 68 yr, 86% were male; mean SV 42 6 12 cm3.
Elective repair in 91% of cases, while 9% treated for rupture
or thrombosis; 56% were asymptomatic, 35% had claudica-
tion and 9% rest pain. Technical success was 98%. At mean
follow-up of 84 months (range, 6 to 138 months) primary,
assisted primary, and secondary patency was 63%, 68%, and
68%; LS was 96% and S 81%. Of the 13 limbs with stent
graft failure, seven required conversion, two underwent
amputation, while four remained with mild claudication.
Of those with graft occlusion, 61% (8 out of 13) of cases
occurred within the ﬁrst year of follow-up. The overall
mean difference in aneurysm SV shrinkage at 7 years was
signiﬁcant (42 6 12 cm3 vs 21 6 8 cm3; P ¼ .02). Theassociation of covering a length >20 cm and distal landing
zone between 1 and 1.5 cm from the take off of the ante-
rior tibial artery (ATA) was a negative predictor for
improved patency (OR, 3.05; 95% CI, 1.9 to 2.3; P ¼
.005).
Conclusions: EVPAR provides successful aneurysm
exclusion with acceptable long term patency, excellent LS
and S. However, close surveillance is required, particularly
within the ﬁrst postoperative year. Patients requiring
coverage >20 cm and a distal landing zone between 1
and 1.5 cm from the ATA may be at increased risk for
failure.
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Objectives: Bone marrow aspirate injections (BMA) in
the treatment of patients with critical limb ischemia (CLI)
is a potential treatment option in poor candidates for stan-
dard revascularization procedures. While clinical trials are
ongoing, there is little comparative data to assess its efﬁcacy
compared to bypass.
Methods: 19 patients with poor revascularization
options underwent BMA. Outcomes were compared to
a cohort of 42 CLI patients undergoing infrainguinal
bypass felt to be at high risk for graft failure (previous
endovascular treatment or bypass, tibial target, and tissue
loss). BMA patients underwent harvest of 120-240 mL of
